Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will
 receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be
 assessed for safety, tolerability, pharmacokinetics, and antiviral activity.
Inclusion Criteria:

 -  Male or female of ages 18 - 65

 -  Chronic HBV infection for >/= 6 months

 Exclusion Criteria:

 -  Any clinically significant chronic or acute medical condition that makes the volunteer
 unsuitable for participation

 -  Significant fibrosis or cirrhosis

 -  History or evidence of drug or alcohol abuse

 -  History of intolerance to SC injection

 -  History of chronic liver disease from any cause other than chronic HBV infection

 -  History of hepatic decompensation

 -  Any prior receipt of an interferon product